{'fraction_non_alphanumeric': 0.02485207100591716, 'fraction_numerical': 0.009467455621301775, 'mean_word_length': 5.991735537190083, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Comparison of thiamazole pharmacokinetics in healthy individuals and patients with hyperthyroidism].

Pharmacokinetic parameters of thiamazole in hyperthyroid patients (40 subjects with Graves-Basedow disease--32 female and 8 male patients) and in healthy individuals (8 subjects--5 women and 3 men) were compared. A one-compartment model was used for the analysis of examined pharmacokinetic parameters. Area under thiamazole concentration curve (AUC) and thiamazole peak plasma concentration (cmax) were significantly decreased in hyperthyroid patients in comparison with healthy individuals. An analysis of other pharmacokinetic parameters suggests that observed differences seem to depend upon lowered and retarded thiamazole absorption from the gut and acceleration of drug metabolism in hepatic microsomal system in hyperthyroid patients.